Tech Company Financing Transactions

Verve Therapeutics Funding Round

Verve Therapeutics, based in Cambridge, scored $94 million from Casdin Capital, Wellington Management Company and Biomatics Capital Partners.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance the company's pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

Company Information

Company Status
Mailing Address
500 Technology Sq. 901
Cambridge, MA 02139
Email Address
Not Recorded
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Verve Therapeutics LinkedIn Company Profile
Social Media
Verve Therapeutics Company Twitter Account
Company News
Verve Therapeutics News
Verve Therapeutics on Facebook
Verve Therapeutics on YouTube

Management Team

Email & Social
Burt Adelman
  Burt Adelman LinkedIn Profile  Burt Adelman Twitter Account  Burt Adelman News  Burt Adelman on Facebook
Chief Executive Officer
Sekar Kathiresan
  Sekar Kathiresan LinkedIn Profile  Sekar Kathiresan Twitter Account  Sekar Kathiresan News  Sekar Kathiresan on Facebook
Chief Scientific Officer
Andrew Bellinger
  Andrew Bellinger LinkedIn Profile  Andrew Bellinger Twitter Account  Andrew Bellinger News  Andrew Bellinger on Facebook
Keith Joung
  Keith Joung LinkedIn Profile  Keith Joung Twitter Account  Keith Joung News  Keith Joung on Facebook
Kiran Musunuru
  Kiran Musunuru LinkedIn Profile  Kiran Musunuru Twitter Account  Kiran Musunuru News  Kiran Musunuru on Facebook
Anthony Philippakis
  Anthony Philippakis LinkedIn Profile  Anthony Philippakis Twitter Account  Anthony Philippakis News  Anthony Philippakis on Facebook
Issi Rozen
  Issi Rozen LinkedIn Profile  Issi Rozen Twitter Account  Issi Rozen News  Issi Rozen on Facebook
Barry Ticho
  Barry Ticho LinkedIn Profile  Barry Ticho Twitter Account  Barry Ticho News  Barry Ticho on Facebook
Andrew Ashe
  Andrew Ashe LinkedIn Profile  Andrew Ashe Twitter Account  Andrew Ashe News  Andrew Ashe on Facebook
Vice President
Kallanthottathil Rajeev
  Kallanthottathil Rajeev LinkedIn Profile  Kallanthottathil Rajeev Twitter Account  Kallanthottathil Rajeev News  Kallanthottathil Rajeev on Facebook
Vice President
Ellen Rohde
  Ellen Rohde LinkedIn Profile  Ellen Rohde Twitter Account  Ellen Rohde News  Ellen Rohde on Facebook
VP - Manufacturing
Christopher Cheng
  Christopher Cheng LinkedIn Profile  Christopher Cheng Twitter Account  Christopher Cheng News  Christopher Cheng on Facebook
VP - Marketing
Michele Rozen
  Michele Rozen LinkedIn Profile  Michele Rozen Twitter Account  Michele Rozen News  Michele Rozen on Facebook
VP - R & D
Alexandra Chadwick
  Alexandra Chadwick LinkedIn Profile  Alexandra Chadwick Twitter Account  Alexandra Chadwick News  Alexandra Chadwick on Facebook
VP - Regulatory Affairs
Leslie Stolz
  Leslie Stolz LinkedIn Profile  Leslie Stolz Twitter Account  Leslie Stolz News  Leslie Stolz on Facebook



Browse more venture capital transactions:

Prev: 1/20/2021: Aledade venture capital transaction
Next: 1/20/2021: Swimlane venture capital transaction


Share this article


Where The Data Comes From

Our team works diligently to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary